The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, recently announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd. ...

Core Viewpoint - Clearmind Medicine Inc. has entered into a development agreement with Polyrizon Ltd. to enhance the bioavailability and clinical advancement of its lead compound MEAI for addiction-related and other CNS disorders [1][2][3] Group 1: Collaboration Details - The agreement involves the application of Polyrizon's proprietary intranasal hydrogel technology to develop an optimized formulation of Clearmind's MEAI [2][3] - The collaboration aims to leverage the advantages of intranasal delivery for CNS-targeted therapeutics, which include enhanced nasal residence time, targeted delivery, and bypassing first-pass metabolism [3][5] Group 2: Company Insights - Clearmind is focused on discovering and developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including addiction and mental health disorders [1][6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Group 3: Technology Overview - Polyrizon specializes in developing innovative medical device hydrogels for nasal delivery, which can provide a barrier against viruses and allergens [7] - Their proprietary Capture and Contain™ hydrogel technology aims to improve bioadhesion and retention at the nasal deposition site for drug delivery [7]

Core Viewpoint - Polyrizon Ltd. has entered into a development agreement with Clearmind Medicine Inc. to leverage Polyrizon's intranasal delivery platform for the clinical development of Clearmind's drug candidate MEAI, aimed at treating addiction-related and other CNS conditions [1][2][3] Group 1: Collaboration Details - The collaboration aims to advance an intranasal formulation of MEAI to support Clearmind's future clinical development programs [2] - Polyrizon's proprietary intranasal technology is designed to enable targeted and efficient delivery of drugs, potentially offering significant value in Clearmind's clinical pathway [3] Group 2: Polyrizon's Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The company's Capture and Contain TM hydrogel technology is designed to enhance bioadhesion and prolong retention at the nasal site for drug delivery [4][6] Group 3: Clearmind's Focus - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address underserved health issues, including alcohol use disorder [7] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [8]

The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd. (" ...

Core Insights - Polyrizon Ltd. has initiated a key usability study for its lead product candidate, NASARIX™, aimed at confirming alignment with FDA requirements and supporting clinical development [1][2] Group 1: Product Development - NASARIX™ is an innovative intranasal allergy blocker designed for broad consumer use, representing a significant advancement in Polyrizon's development roadmap [1][2] - The usability study is intended to de-risk downstream regulatory review and facilitate a streamlined path toward clinical trials [2][3] Group 2: Regulatory Milestones - Successful completion of the usability program will provide essential regulatory evidence for NASARIX™'s readiness for clinical evaluation, with trials expected to commence in Q3 2026 [3][4] - The study underscores the company's commitment to FDA-aligned development, patient safety, and user-centered solutions [4] Group 3: Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain™ hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development focused on enhancing bioadhesion and retention [4]

Core Insights - Polyrizon Ltd. is committed to advancing its core intranasal medical pipeline while exploring strategic investment opportunities in sectors such as aviation, AI, and defense [1][2][3] - The company is focusing on high-potential sectors for initial investment efforts, while continuing to develop its medical devices, including products like PL-14 and PL-16 [2][3] - Polyrizon's Board of Directors has approved selective investments aimed at generating near-term revenues and enhancing financial stability, leveraging the company's strong cash position and debt-free balance sheet [3] Company Overview - Polyrizon is a development-stage biotech company specializing in innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain TM hydrogel technology is designed to function as a "biological mask" in the nasal cavity, with ongoing development to improve bioadhesion and drug delivery [4]

Core Insights - Polyrizon Ltd. has completed the branding process for its PL-14 allergy blocker, which will be marketed as NASARIX™ [1][4] - NASARIX™ utilizes Polyrizon's proprietary Capture and Contain™ hydrogel technology, designed to create a protective barrier against allergens and viruses [2][5] - The establishment of the NASARIX™ brand is a significant milestone for Polyrizon, aiding in future commercialization and effective communication of the product's benefits [2][4] Company Overview - Polyrizon is a pre-clinical-stage biotechnology company focused on developing innovative medical device hydrogels delivered as nasal sprays [5] - The company's C&C hydrogel technology aims to provide a barrier against viruses and allergens, functioning as a "biological mask" in the nasal cavity [5] - Polyrizon is also developing additional technology for nasal delivery of active pharmaceutical ingredients, referred to as Trap and Target™ [5]

Core Insights - Polyrizon Ltd. announced positive results from a pre-clinical study evaluating its PL-14 Allergy Blocker formulation, demonstrating its effectiveness in blocking allergens compared to hydroxypropyl methylcellulose (HPMC) [1][5]. Study Findings - The study utilized a validated in-vitro Transwell permeability system to assess PL-14's ability to inhibit the transfer of Der p 1, a significant house dust mite allergen associated with allergic rhinitis and asthma [2]. - PL-14 significantly reduced allergen transfer at all time points compared to HPMC, with statistical significance (p-values ≤ 0.0042) observed at 1, 2, 4, 6, and 24 hours [3][9]. - At 1 hour, PL-14 showed a mean allergen concentration of approximately 20.6 ng, while HPMC had a concentration of about 1354.4 ng. By 24 hours, HPMC's concentration rose to around 5201.2 ng, indicating limited barrier function [9]. Product Development - The results support the continued advancement of PL-14 as a preventive approach for allergic rhinitis by reducing allergen penetration through a synthetic surface [6]. - Polyrizon is advancing its preclinical development program and plans to support future clinical studies to establish PL-14's regulatory pathway and clinical benefits for allergy prevention [6]. Company Overview - Polyrizon is a development-stage biotechnology company focused on innovative medical device hydrogels delivered as nasal sprays, creating a barrier against viruses and allergens [7]. - The company's proprietary Capture and Contain TM hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development to enhance bioadhesion and retention for drug delivery [7].

Industry Overview - The 2025-2026 flu season in the United States is intensifying, primarily driven by a mutated strain of influenza A, leading to concerns about a challenging winter ahead [1] - As of late December 2025, the CDC estimates indicate that flu has caused at least 4.6 million illnesses, 49,000 hospitalizations, and 1,900 deaths nationwide [1][2] - Flu activity is rising sharply, with outpatient visits for influenza-like illness significantly above baseline levels in many states [2] Vaccination and Public Health - Vaccination rates are lagging, with over 47 million doses administered, down approximately 3 million from the previous year, increasing vulnerability among the population [2] - The World Health Organization reports a global increase in influenza activity since October 2025, with influenza A viruses being the most prevalent [3] Company Spotlight: Polyrizon Ltd. - Polyrizon Ltd. is an Israeli biotech company developing innovative medical device hydrogels, specifically the PL-16 Viral Blocker, a non-pharmaceutical hydrogel nasal spray [4][8] - The PL-16 product creates a temporary physical barrier on the nasal mucosa, potentially capturing and containing respiratory viruses before they can infect cells, showing over 90% protection in preclinical studies [5][6] - On December 19, 2025, Polyrizon submitted a Pre-Request for Designation to the FDA for PL-16, aiming for potential over-the-counter status to reduce exposure to respiratory viruses [6] Market Potential and Innovation - The PL-16 product is designed to complement existing vaccines, masks, and hygiene practices, providing an additional layer of defense during high-activity seasons [6][7] - Experts emphasize the importance of layered protection, suggesting that innovations like Polyrizon's PL-16 could serve as a drug-free tool for both vaccinated and unvaccinated individuals [7]

Core Viewpoint - Polyrizon Ltd. is advancing its core medical pipeline while exploring investment opportunities in revenue-generating assets to enhance shareholder value [1][3]. Product Development - The company is committed to its core medical device activities, focusing on the development of products such as PL-14 (allergy blocker), PL-16 (viral blocker), and the Trap & Target platform for intranasal drug delivery [2][3]. Strategic Initiatives - The Board of Directors has authorized the exploration of investments in assets expected to generate revenues, aiming to utilize the company's resources efficiently for growth and long-term shareholder value [3]. Technology Overview - Polyrizon specializes in innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens in the nasal cavity [4]. - The proprietary Capture and Contain TM hydrogel technology is designed to function as a "biological mask" and is being further developed for enhanced bioadhesion and drug delivery [4].